Patent application number | Description | Published |
20080269495 | Process for Preparation of Piperidine Carboxylic Acid - A process for preparing pure tiagabine, which is a piperidine carboxylic acid compound, via pharmaceutically acceptable salts of tiagabine ester is provided. Also, L(+) tartaric acid, oxalic acid and dibenzoyl L(+) tartaric acid salts of tiagabine esters are provided. Further, process for preparing acid addition salts of tiagabine esters is provided. | 10-30-2008 |
20080312254 | Process for the Preparation of Ziprasidone - The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia. | 12-18-2008 |
20090216029 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM - A process for the production of amorphous atorvastatin calcium and stabilized, amorphous atorvastatin calcium is provided. | 08-27-2009 |
20090259047 | BARIUM SALT OF BENZIMIDAZOLE DERIVATIVE - The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared. | 10-15-2009 |
20100137607 | BARIUM SALT OF BENZIMIDAZOLE DERIVATIVE - The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)- | 06-03-2010 |
20100305328 | PROCESS FOR PREPARATION OF PIPERIDINE CARBOXYLIC ACID - Processes for preparing pure tiagabine, a piperidine carboxylic acid, using pharmaceutically acceptable acid addition salts of tiagabine esters are provided. L(+)-tartaric acid, oxalic acid and dibenzoyl L(+)-tartaric acid addition salts of tiagabine esters are also provided. Further, processes for preparing acid addition salts of tiagabine esters are provided. | 12-02-2010 |
20110086884 | BARIUM SALT OF BENZIMIDAZOLE DERIVATIVE - The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared. | 04-14-2011 |
20110190296 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors - The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms. | 08-04-2011 |
20110190369 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors - The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms. | 08-04-2011 |
20110207933 | PROCESS FOR THE PREPARATION OF ZIPRASIDONE - The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia. | 08-25-2011 |